| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,985,831 ) |
| | 2025 | 2025 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 001 | 6 | NIH | 2/13/2025 | $1,985,831 |
| | 2025 | 2023 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 5 | NIH | 10/15/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = -$2,038 ) |
| | 2024 | 2023 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 5 | NIH | 10/20/2023 | $0 |
| | 2024 | 2021 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44ES030642 | Development of a Genotoxicity Assay using Duplex Sequencing | 000 | 3 | NIH | 10/19/2023 | -$2,038 |
|
| Issue Date FY: 2023 ( Subtotal = $1,139,103 ) |
| | 2023 | 2023 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 001 | 5 | NIH | 8/15/2023 | $1,139,103 |
| | 2023 | 2021 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 4 | NIH | 5/11/2023 | $0 |
| | 2023 | 2020 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 4 | NIH | 11/21/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = -$12,186 ) |
| | 2022 | 2020 | TWINSTRAND BIOSCIENCES INC | 3131 ELLIOTT AVE | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 4 | NIH | 10/28/2021 | -$12,186 |
|
| Issue Date FY: 2021 ( Subtotal = $1,479,410 ) |
| | 2021 | 2021 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44ES030642 | Development of a Genotoxicity Assay using Duplex Sequencing | 000 | 3 | NIH | 7/20/2021 | $619,680 |
| | 2021 | 2021 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 002 | 4 | NIH | 7/28/2021 | $249,982 |
| | 2021 | 2021 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 001 | 4 | NIH | 3/23/2021 | $30,486 |
| | 2021 | 2021 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 4 | NIH | 1/13/2021 | $579,262 |
| | 2021 | 2020 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 4 | NIH | 3/31/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,786,430 ) |
| | 2020 | 2020 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44ES030642 | Development of a Genotoxicity Assay using Duplex Sequencing | 001 | 2 | NIH | 8/20/2020 | $874,368 |
| | 2020 | 2020 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 4 | NIH | 8/13/2020 | $221,887 |
| | 2020 | 2020 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 3 | NIH | 12/23/2019 | $690,175 |
| | 2020 | 2019 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44ES030642 | Development of a Genotoxicity Assay using Duplex Sequencing | 000 | 1 | NIH | 6/15/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,869,232 ) |
| | 2019 | 2019 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 3 | NIH | 9/5/2019 | $819,300 |
| | 2019 | 2019 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44ES030642 | Development of a Genotoxicity Assay using Duplex Sequencing | 000 | 1 | NIH | 7/11/2019 | $224,797 |
| | 2019 | 2019 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 3 | NIH | 9/5/2019 | $134,960 |
| | 2019 | 2019 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 001 | 2 | NIH | 5/2/2019 | $690,175 |
| | 2019 | 2018 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 1 | NIH | 5/2/2019 | $0 |
| | 2019 | 2018 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 002 | 1 | NIH | 7/17/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,123,643 ) |
| | 2018 | 2018 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA233381 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | 000 | 1 | NIH | 7/16/2018 | $299,790 |
| | 2018 | 2018 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 001 | 2 | NIH | 9/14/2018 | $823,853 |
| | 2018 | 2017 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 1 | NIH | 9/13/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $295,409 ) |
| | 2017 | 2017 | TWINSTRAND BIOSCIENCES, INC. | 3131 ELLIOT AVE STE 750 | SEATTLE | WA | 98121-1095 | KING | USA | R44CA221426 | Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | 000 | 1 | NIH | 8/29/2017 | $295,409 |
|
|
